[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-381940-105":59,"doc-detail-381940-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","advances-in-cart-cell-therapy-for-treating-patients-with-mantle-cell-lymphoma-a-critical-appraisal","Advances in CART-cell therapy for treating patients with mantle cell lymphoma - a critical appraisal","","The editorial reviews CAR T-cell (chimeric antigen receptor T-cell) therapy as an emerging immunotherapy for mantle cell lymphoma (MCL), a rare, heterogeneous non-Hodgkin lymphoma characterized by cyclin D1 (CCND1) overexpression due to an IGH-CCND1 chromosomal translocation. It outlines how CAR T cells are engineered to recognize tumor-associated antigens and kill antigen-expressing cancer cells, highlighting outcomes in relapsed/refractory disease. Key data discussed include ZUMA-2 results for axi-cel and TRANSCEND NHL 001 findings for liso-cel, plus approvals and safety considerations for brexu-cel.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/advances-in-cart-cell-therapy-for-treating-patients-with-mantle-cell-lymphoma-a-critical-appraisal/381940/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/advances-in-cart-cell-therapy-for-treating-patients-with-mantle-cell-lymphoma-a-critical-appraisal/381940.png","ImageObject",300,407,{"name":92,"@type":93},"Guten tag","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-09-28","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":8},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the biological basis of mantle cell lymphoma described in the editorial?","Question",{"text":112,"@type":113},"The editorial describes MCL as distinguished by cyclin D1 (CCND1) overexpression caused by a chromosomal translocation between IGH and CCND1, leading to abnormal B-cell production of excessive CCND1.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does CAR T-cell therapy work for patients with MCL?",{"text":117,"@type":113},"CAR T-cell therapy involves genetically altering a patient’s T cells to express a tumor-associated antigen-specific chimeric antigen receptor, then reinfusing them so they distinguish and kill cancer cells expressing the target antigens.",{"name":119,"@type":110,"acceptedAnswer":120},"Which clinical trials and CAR T-cell products are highlighted for relapsed or refractory MCL?",{"text":121,"@type":113},"The editorial highlights ZUMA-2 for axicabtagene ciloleucel (axi-cel) and TRANSCEND NHL 001 for lisocabtagene maraleucel (liso-cel), and it also discusses approvals and outcomes for brexucabtagene autoleucel (brexu-cel/KTE-X19).","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},381940,1790613079,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":8,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":81,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":39},687212321768,"https://ap-avatar.wpscdn.com/avatar/a0010bdbe886d2fe77?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789897067658708522","’Editorial  \nAdvances in CART-cell therapy for treating patients with mantle cell lymphoma: a critical appraisal  \nRuhul Amin, PhDa , Ronald Darwin, PhDb , Sandip Chakraborty, MVScc , Abhijit Dey, PhDd , Kuldeep Dhama, PhDe,* , Talha Bin Emran, PhDf,g,*  \nCAR T-cell (chimeric antigen receptor T-cell) has shown encouraging outcomes in the treatment of several cancers, including mantle cell lymphoma (MCL) that is a rare type of non-Hodgkin lymphoma (NHL) which begins in the lymph nodes. It is distinguished by cyclin D1 protein overexpression caused by a chromosomal translocation between the immunoglobulin heavy chain locus (IGH) and Cyclin D1 (CCND1) gene. In the case of MCL, excessive CCND1 is produced by B cells that are abnormal. Notably, CCND1 helps in the growth of B cells. Clinical characterization of MCL is done by its heterogeneity nature. The course of the disease ranges from indolent cases for which therapy is not essential for years to MCL that is highly aggressive in nature (requiring treatment), with the prognosis very limited. New targeted immunotherapy-based approaches, viz., CAR T-cell therapy, have already facilitated the improvement of the therapeutic options, particularly for the refractory or relapsing disease[1] .  \nCAR T-cell treatment includes genetically altering a patient’sown T cells to express a tumor-associated antigen-specific chimeric antigen receptor. Then, the CAR T cells are injected back into the patient, where they distinguish and kill cancer cells expressing specific antigens (Fig. 1) . Notably, advanced immunotherapy with the use of CAR T cells is found to be fruitful for patients who suffer from MCL. Importantly, in comparison to other drugs that exist, CAR T-cell therapy is found to be successful in managing MCL resistance[2] . A feasible approach in the case of MCL that is re-  \naFaculty of Pharmaceutical Science, Assam down town University, Panikhaiti, Gandhinagar, Guwahati, Assam, bSchool of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies, Chennai, cDepartment of Veterinary Microbiology, College of Veterinary Sciences and Animal Husbandry, R.K. Nagar, West Tripura, Tripura, dDepartment of Life Sciences, Presidency University, Kolkata, West Bengal, eDivision of Pathology, ICAR-Indian Veterinary Research Institute, Bareilly, Izatnagar, Uttar Pradesh, India, fDepartment of Pharmacy, BGC Trust University Bangladesh, Chittagong and gDepartment of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Dhaka, Bangladesh  \nSponsorships or competing interests that maybe relevant to content are disclosed atthe end of this article.  \n*Corresponding author. Address: Department of Pharmacy, BGC Trust University Bangladesh, Chittagong 4381, Bangladesh. E-mail: [talhabmb@bgctub.ac.bd](talhabmb@bgctub.ac.bd)[ ](talhabmb@bgctub.ac.bd)(T.B. Emran); Division of Pathology, Indian Veterinary Research Institute, Izatnagar 243122, Bareilly, Uttar Pradesh, [India. E-mail: kdhama@rediffmail.com](India. E-mail: kdhama@rediffmail.com) (K. Dhama).  \nCopyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution-ShareAlike License 4.0, which allows others to remix, tweak, and build upon the work, even for commercial purposes, as long as the author is credited and the new creations are licensed under the identical terms.  \nInternational Journal of Surgery (2023) 109:3742–3744  \nReceived 8 August 2023; Accepted 8 August 2023  \nPublished online 2 September 2023  \n[http://dx.doi.org/10.1097/JS9.0000000000000691](http://dx.doi.org/10.1097/JS9.0000000000000691)  \noccurring in nature is to target B cell antigens on the surface of the cells. This approach has provided scientists with significant responses in other cancers of B cells too.  \nIn the ZUMA-2 study, patients suffering from relapsed or refractory MCL when given axicabtagene ciloleucel (axi-cel) (an example of autologo","cbCaii6NsIYoQhAF","https://ap.wps.com/l/cbCaii6NsIYoQhAF","pdf",319570,"English","# Editorial overview\n## CAR T-cell approach and rationale for MCL\n## Clinical trial evidence and regulatory approvals","[{\"question\":\"What is the biological basis of mantle cell lymphoma described in the editorial?\",\"answer\":\"The editorial describes MCL as distinguished by cyclin D1 (CCND1) overexpression caused by a chromosomal translocation between IGH and CCND1, leading to abnormal B-cell production of excessive CCND1.\"},{\"question\":\"How does CAR T-cell therapy work for patients with MCL?\",\"answer\":\"CAR T-cell therapy involves genetically altering a patient’s T cells to express a tumor-associated antigen-specific chimeric antigen receptor, then reinfusing them so they distinguish and kill cancer cells expressing the target antigens.\"},{\"question\":\"Which clinical trials and CAR T-cell products are highlighted for relapsed or refractory MCL?\",\"answer\":\"The editorial highlights ZUMA-2 for axicabtagene ciloleucel (axi-cel) and TRANSCEND NHL 001 for lisocabtagene maraleucel (liso-cel), and it also discusses approvals and outcomes for brexucabtagene autoleucel (brexu-cel/KTE-X19).\"}]","Advances in CART-cell therapy for treating patients with mantle cell lymphoma - a critical appraisal | PDF",1790247906]